Editorial

Is this Adverse Drug Reaction as Clear Cut as Previously Thought?

Authors: Steven Joseph Haas, BPharm, BPharmSci(Hons), MSHPA, MAEA

Abstract

“Doctor, we may have a problem.” It is a statement that strikes fear into the heart of any medical practitioner, but is frequently encountered with respect to adverse drug reactions. It is perfectly reasonable for the medical profession to expect that a medication will help or heal rather than harm; however, adverse reactions are a leading cause for increased morbidity and mortality worldwide.1–4

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279:1200–1205.
 
2. Malhotra S, Jain S, Pandhi P. Drug-related visits to the medical emergency department: a prospective study from India. Int J Clin Pharmacol Ther 2001;39:12–18.
 
3. Runciman WB, Roughead EE, Semple SJ, et al. Adverse drug events and medication errors in Australia. Int J Qual Health Care 2003;15(suppl 1):i49–i59.
 
4. van der Hooft CS, Sturkenboom MC, van Grootheest K, et al. Adverse drug reaction-related hospitalisations: a nationwide study in The Netherlands. Drug Saf 2006;29:161–168.
 
5. Finsterer J, Gelpi E. Mitochondrial disorder aggravated by propranolol. South Med J 2006;99:768–771.
 
6. Le Quintrec JS, Le Quintrec JL. Drug-induced myopathies. Baillieres Clin Rheumatol 1991;5:21–38.
 
7. England JD, Walsh JC, Stewart P, et al. Mitochondrial myopathy developing on treatment with the HMG CoA reductase inhibitors: simvastatin and pravastatin. Aust N Z J Med 1995;25:374–375.
 
8. Parra D, Gonzalez A, Mugueta C, et al. Laboratory approach to mitochondrial diseases. J Physiol Biochem 2001;57:267–284.
 
9. Lucas RM, McMichael AJ. Association or causation: evaluating links between ‘environment and disease’. Bull World Health Organ 2005;83:792–795.
 
10. Rothman KJ, Greenland S. Causation and causal inference in epidemiology. Am J Public Health2005;95(suppl 1):S144–S150.